Top

Published in:

Open Access 01-12-2014 | Research article

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

Authors: Philippe Manceau, Clotilde Latarche, Sophie Pittion, Gilles Edan, Jérôme de Sèze, Catherine Massart, Marc Debouverie

Published in: BMC Neurology | Issue 1/2014

Abstract

Background

The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNβ, NAb and fatigue.

Methods

Patients with relapsing-remitting MS on IFNβ treatment were included. During the second year of treatment, the patients were analyzed for NAb status and non-response criteria to IFNβ (number of relapses ≥1 during the follow-up period, increase in the Expanded Disability Status Scale ≥0.5). The score on the Modified Fatigue Impact Scale (MFIS pathological if score ≥35) was noted for each patient.

Results

Of the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNβ, and 57.4% had a pathological MFIS score. Fatigue was increased in NAb + patients (p = 0.0014) and they were more likely to present non-response criteria to IFNβ (p = 0.041) than NAb- patients. Multivariate logistic regression analysis showed that the presence of NAb was related to fatigue (p = 0.0032) and denoted disease activity in these patients (p = 0.026).

Conclusions

This study demonstrates the impact of NAb on the non-clinical response to IFNβ. Fatigue assessment is an indicator of IFNβ responsiveness and a predictive biomarker of deterioration on patient’s neurological status.

Available only for authorised users

Schellekens H, Casadevall N: Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004, 251 (Suppl 2): II4-II9.PubMed

Neutralizing antibodies falling on treatment of multiple sclerosis with interferon beta-1b: experience falling on the first three years. Neurology. 1996, 47 (4): 889-894.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert GR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996, 39 (3): 285-294.CrossRefPubMed

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD: Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998, 50 (5): 1266-1272.CrossRefPubMed

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998, 352 (9139): 1498-1504.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW: Intramuscular interferon beta-1a therapy initiated falling on a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000, 343 (13): 898-904.CrossRefPubMed

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Couthino MF, Tsao EC, Sandrock AW: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology. 2002, 59 (10): 1507-1517.CrossRefPubMed

Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinschenker B: Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002, 59 (10): 1496-1506.CrossRefPubMed

Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003, 362 (9391): 1184-1191.CrossRefPubMed

10.

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A: Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004, 62 (11): 2031-2037.CrossRefPubMed

11.

Freedman MS, Francis GS, Sanders EA, Rice GP, O’Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O’Brien F: Randomized study of once-weekly interferon beta-1Ia therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler. 2005, 11 (1): 41-45.CrossRefPubMed

12.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalban X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C: Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 2011, 77 (9): 835-843.CrossRefPubMed

13.

Hegen H, Schleiser M, Gneiss , Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F: Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler. 2012, 18 (5): 610-615.CrossRefPubMed

14.

Sato DK, Nakashima I, Fukazawa T, Shimizu Y, Tomizawa Y, Yokoyama K, Misu T, Creeke PI, Farrell R, Giovannoni G, Itoyama Y, Fujihara K, Aoki M: Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. Tokohu J Exp Med. 2012, 228 (2): 85-92.CrossRef

15.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmensen KM, Bendtzen K: Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005, 65 (1): 33-39.CrossRefPubMed

16.

Van der Meide PH, Schellekens H: Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy. 1997, 10 (1): 39-48.CrossRefPubMed

17.

Francis GS, Rice GP, Alsop JC: Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005, 65 (1): 48-55.CrossRefPubMed

18.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005, 65 (1): 40-47.CrossRefPubMed

19.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sorensen PS: Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010, 9 (7): 740-750.CrossRefPubMed

20.

Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV: Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler. 2002, 8 (6): 523-526.CrossRefPubMed

21.

Boërio D, Lefaucheur JP, Hogrel JY, Créange A: Pathophysiology and treatment of fatigue in multiple sclerosis. Rev Neurol. 2006, 162 (3): 311-320.CrossRefPubMed

22.

Krupp L: Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006, 12 (4): 367-368.CrossRefPubMed

23.

Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ: The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994, 21 (1): 9-14.CrossRefPubMed

24.

Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM: Fatigue in multiple sclerosis: an example of cytokine mediated sickness behavior?. J Neurol Neurosurg Psychiatry. 2006, 77 (1): 34-39.CrossRefPubMedPubMedCentral

25.

Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P: Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004, 10 (2): 165-169.CrossRefPubMed

26.

Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H: Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci. 2006, 243 (1-2): 39-45.CrossRefPubMed

27.

Debouverie M, Pittion-Vouyovitch S, Brissart H, Guillemin F: Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis. J Neurol. 2008, 255 (5): 633-636.CrossRefPubMed

28.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005, 58 (6): 840-846.CrossRefPubMed

29.

Matthews WB: Symptoms and signs. McAlpine’s Multiple Sclerosis. Edited by: Matthews WE. 1991, Churchill Livingstone, Edinburgh, 61-63. 2

30.

Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL: Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci. 1965, 122: 552-568.CrossRefPubMed

31.

Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F: Validity of a French version of the fatigue impact scale in multiple sclerosis. Mult Scler. 2007, 13 (8): 1026-1032.CrossRefPubMed

32.

Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M: Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand. 2006, 113 (3): 156-162.CrossRefPubMed

33.

Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389.CrossRefPubMed

34.

Pellet J, Bobon DP, Mormont I, Lang F, Massardier A: Étude Princeps de Validation Française de la MADRS: Sous-Échelle Dépression de la CPRS. Congrès de psychiatrie et de neurologie de langue française Reims. 1980

35.

Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J: Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods. 2008, 336 (2): 113-118.CrossRefPubMed

36.

Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N: The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res. 2001, 21 (9): 729-742.CrossRefPubMed

37.

Etemadifar M, Janghorbani M, Shaygannejad V: Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006, 113 (5): 283-287.CrossRefPubMed

38.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE: Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. Mult Scler. 2011, 17 (3): 353-360.CrossRefPubMed

39.

Flachenecker P, Meissner H: Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler. 2008, 14 (2): 274-277.CrossRefPubMed

40.

Capobianco M, Rizzo A, Malucchi S, Sperli F, Di Sapio A, Oqqero A, Zaffaroni M, Ghezzi A, Bertolotto A: Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurol Sci. 2008, 29 (Suppl 2): S227-S229.CrossRefPubMed

41.

Kos D, Kerckhofs E, Nagels G, D'Hoogue MB, Ilsbroukx S: Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008, 22 (1): 91-100.CrossRefPubMed

42.

Andreasen AK, Stenager E, Dalgas U: The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler. 2011, 17 (9): 1041-1054.CrossRefPubMed

Title: Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
Authors: Philippe Manceau
Clotilde Latarche
Sophie Pittion
Gilles Edan
Jérôme de Sèze
Catherine Massart
Marc Debouverie
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-014-0215-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Sjögren’s syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) - a case report and review of literature

Secondary brain abscess following simple renal cyst infection: a case report

Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items

Subcortical white matter infarcts predict 1-year outcome of fatigue in stroke

Clinical significance of cerebrovascular complications in patients with acute infective endocarditis: a retrospective analysis of a 12-year single-center experience